Probably for one IP like ALA and they haven't even started Ph1 clinical trial. HER-Vaxx has completed Ph2 clinical trial with good final result, PD1-Vaxx is about to commence sponsor Ph2 clinical trial, CF33 has produced excellent Ph1 clinical trial update, OnCARlytics is pending for Ph1 clinical trial update, Azer-Cel is close to registrational clinical trial which is consider Ph2/3. VAXINIA has received Fast Track designation and ODD, Azer-Cel has received Fast Track designation. You think all these development for multiple IP is only worth $50-100M.......clueless.
IMU Price at posting:
1.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)